RESULTS: Overall response rate of ONS is 35.7-100%, 17-100%, and 63-100% in patients with cluster headache, chronic migraine and occipital neuralgia respectively. Regarding the long-term effectivity in all groups, 41.6-88.0% of patients remain responders after ≥ 18.3 months. The most frequently reported adverse events include lead migration/fracture (13%) and local pain (7.3%). Based on our results, ONS can be considered a safe and effective treatment for chronic intractable headache disorders. To support more widespread application of ONS, additional research with larger sample sizes should be conducted.
结果:ONS的总体反应率为35.7-100%,17-100%,丛集性头痛患者的比例为63-100%,慢性偏头痛和枕神经痛。关于所有群体的长期有效性,41.6-88.0%的患者在≥18.3个月后仍然有反应。最常报告的不良事件包括导线迁移/断裂(13%)和局部疼痛(7.3%)。根据我们的结果,ONS可被认为是治疗慢性顽固性头痛的安全有效的方法。为了支持ONS更广泛的应用,应进行更大样本量的额外研究。